Robert Wilkins, MD
Interventional Cardiology · Hattiesburg, MSNPI 1598875304
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 211 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,209 and has fallen 68.9% since, to $376 in 2025. That places this record below the midpoint for interventional cardiology clinicians in MS, where the typical reported total is $7,952.
Across 211 payments — averaging $21.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$879
- Inari Medical, Inc.$652
- Boston Scientific$599
- Philips North America LLC$504
- Medtronic$322
- Novartis$277
- plus $1K from 21 others
Across 83 payments — averaging $1227.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cardiovascular Systems Inc.$56K
- Surmodics, Inc.$43K
- Abbott$2K
- Medtronic$1K
What the payments were for
- Food & beverage$4,51198%
- Gifts$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 60 | $879 |
| Inari Medical, Inc. | 25 | $652 |
| Boston Scientific | 34 | $599 |
| Philips North America LLC | 7 | $504 |
| Medtronic(2 entities) | 15 | $322 |
| Novartis | 20 | $277 |
| Abbott | 13 | $268 |
| Cardiva Medical, Inc. | 1 | $201 |
| Venturemed Group, Inc. | 1 | $150 |
| Edwards Lifesciences | 2 | $117 |
| Chiesi USA, Inc. | 3 | $99 |
| Merck | 4 | $77 |
| Shockwave Medical, Inc | 3 | $71 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $48 |
| Astellas Pharma US Inc | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Boehringer Ingelheim | 3 | $43 |
| Terumo Medical Corporation | 2 | $28 |
| Celonova Biosciences, Inc. | 1 | $27 |
| Recor Medical Inc | 1 | $21 |
| Bracco Diagnostics Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| Biosense Webster, Inc. | 1 | $18 |
| Bayer | 1 | $18 |
| Stryker | 1 | $16 |
| Pfizer | 1 | $13 |
| W. L. Gore & Associates, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,586 in reported general payments places this provider in the 25th percentile of 65 interventional cardiology providers in Mississippi.
See all interventional cardiology providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 563 | $485,840 |
| EntrestoSacubitril/Valsartan | 174 | $143,701 |
| XareltoRivaroxaban | 114 | $87,541 |
| BrilintaTicagrelor | 145 | $80,223 |
| JardianceEmpagliflozin | 20 | $22,391 |
| Ranolazine ErRanolazine | 151 | $7,990 |
| ClopidogrelClopidogrel Bisulfate | 721 | $4,722 |
| Amiodarone Hcl | 311 | $3,965 |
| Metoprolol Succinate | 357 | $3,677 |
| Atorvastatin Calcium | 245 | $1,380 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 172 | $1,260 |
| Propafenone Hcl | 28 | $1,121 |
| Metoprolol Tartrate | 346 | $1,038 |
| Nitroglycerin | 81 | $1,038 |
| Carvedilol | 194 | $931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $13 | $485,840563 claims |
| NovartisEntresto | $277 | $143,701174 claims |
| Boehringer IngelheimJardiance | $43 | $22,39120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 65 interventional cardiology providers in Mississippi.
Other interventional cardiology in Hattiesburg
- Christopher DouglasHattiesburg$20K
- Patrick DauphinHattiesburg$9K
- George BlairHattiesburg$5K
- Craig ThielingHattiesburg$5K
- Arthur MartinHattiesburg$3K
- Thad WaitesHattiesburg$3K
- Eric EngerHattiesburg$1K
- John WinscottJackson$482K
- William CrowderJackson$331K
- Foluso FakoredeCleveland$298K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.